Dabigatran in Atrial Fibrillation: New Kid on the Block

Foerster V . New anticoagulants for stroke prevention in patients with atrial fibrillation. Issues in emerging health technologies 2010; issue 116. Available: http://cadth.ca/media/pdf/R0004_Anticoagulants_Atrial_fibrillation_cetap_e.pdf (accessed January 26, 2011).

Holmes DR Jr. Atrial fibrillation and stroke management: present and future. Semin Neurol 2010;30:528–36.

Marsh JD Keyrouz SG . Stroke prevention and treatment. J Am Coll Cardiol 2010;56:683–91.

Ezekowitz MD Aiken TH Brown A Ellis Z . The evolving field of stroke prevention in patients with atrial fibrillation. Stroke 2010;41[suppl 1]:S17–S20.

Bungard TJ Gardner L Archer SL Evaluation of a pharmacist-managed anticoagulation clinic: improving patient care. Open Med 2009;3(1):16–21.

Fogarty PF Minichiello T . Chapter 14: Disorders of hemostasis, thrombosis & antithrombotic therapy. In: McPhee SJ Papakakis MA Rabow MW Cucina R . Current Medical Diagnosis & Treatment 2011. McGraw-Hill Companies, inc.; 2011.

Pradax product monograph. e-CPS. Available: www.e-therapeutics.ca (accessed January 20, 2012).

Eisert WG Hauel N Stangier J Dabigatran: a novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010;30:1885–9.

Siddiqui FM Qureshi AI . Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. Expert Opin pharmacother 2010;11(8):1403–11.

Connolly SJ Ezekowitz MD Yusuf S . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51.

Wallentin L Yusuf S Ezekowitz MD Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control from stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975–85.

Dolan G Smith LA Collins S Plumb JM . Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature. Curr Med Res Opin 2008;24(5):1459–72.

Connolly SJ Ezekowitz MD Yusuf S . Newly identified events in the RE-LY Trial. N Engl J Med 2010;363:1875–6.

Hohnloser SH Oldgren J Yang S Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation 2012;125:669–76.

Cairns JA Connolly S McMurtry S . Canadian Cardiovascular Society Atrial fibrillation Guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011;27:74–90.

U.S. Food and Drug Administration. FDA Drug Safety Pod-cast for Healthcare Professionals: safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). Available: www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm283151.htm (accessed January 20, 2012).

O'Riordan M . FDA investigating serious bleeding events with dabigatran. Available: www.medscape.com/viewarticle/754953 (accessed January 20, 2012).

Institute for Safe Medication Practices. ISMP Medication Safety Alert. Quarterwatch (first quarter 2011) signals for dabigatran and metoclopramide. Available: www.ismp.org/News-letters/acutecare/showarticle.asp?ID=12 (accessed January 20, 2012).

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients with Atrial fibrillation who Completed RE-LY Trial. Available: http://clinicaltrials.gov/ct2/show/NCT00808067 (accessed June 6, 2011).

Canadian Agency for Drugs and Technologies in Health. Common Drug Review. CEDAC final Recommendation. Dabigatran etexilate. New indication: prevention of stroke and systemic embolism in patients with atrial fibrillation. Available: www.cadth.ca/media/cdr/…/cdr_complete_Pradax_June-27-11.pdf/ (accessed January 20, 2012).